SE9304060D0 - Sätt att selektera specifika bakteriofager - Google Patents

Sätt att selektera specifika bakteriofager

Info

Publication number
SE9304060D0
SE9304060D0 SE9304060A SE9304060A SE9304060D0 SE 9304060 D0 SE9304060 D0 SE 9304060D0 SE 9304060 A SE9304060 A SE 9304060A SE 9304060 A SE9304060 A SE 9304060A SE 9304060 D0 SE9304060 D0 SE 9304060D0
Authority
SE
Sweden
Prior art keywords
phage
pct
molecule
protein
methods
Prior art date
Application number
SE9304060A
Other languages
English (en)
Swedish (sv)
Inventor
Carl A K Borrebaeck
Original Assignee
Bioinvent Int Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioinvent Int Ab filed Critical Bioinvent Int Ab
Priority to SE9304060A priority Critical patent/SE9304060D0/xx
Publication of SE9304060D0 publication Critical patent/SE9304060D0/xx
Priority to AU12521/95A priority patent/AU686292B2/en
Priority to EP95903485A priority patent/EP0739413B1/de
Priority to US08/640,792 priority patent/US5712089A/en
Priority to CA002178205A priority patent/CA2178205A1/en
Priority to JP51614195A priority patent/JP3574135B2/ja
Priority to DK95903485T priority patent/DK0739413T3/da
Priority to PCT/SE1994/001166 priority patent/WO1995016027A1/en
Priority to DE69417446T priority patent/DE69417446T2/de
Priority to ES95903485T priority patent/ES2132601T3/es
Priority to AT95903485T priority patent/ATE178092T1/de
Priority to GR990401295T priority patent/GR3030210T3/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
SE9304060A 1993-12-06 1993-12-06 Sätt att selektera specifika bakteriofager SE9304060D0 (sv)

Priority Applications (12)

Application Number Priority Date Filing Date Title
SE9304060A SE9304060D0 (sv) 1993-12-06 1993-12-06 Sätt att selektera specifika bakteriofager
AT95903485T ATE178092T1 (de) 1993-12-06 1994-12-05 Methode zur selektion spezifischer bakteriophagen
CA002178205A CA2178205A1 (en) 1993-12-06 1994-12-05 Method of selecting specific bacteriophages
EP95903485A EP0739413B1 (de) 1993-12-06 1994-12-05 Methode zur selektion spezifischer bakteriophagen
US08/640,792 US5712089A (en) 1993-12-06 1994-12-05 Method of selecting specific bacteriophages
AU12521/95A AU686292B2 (en) 1993-12-06 1994-12-05 Method of selecting specific bacteriophages
JP51614195A JP3574135B2 (ja) 1993-12-06 1994-12-05 特異的バクテリオファージの選択方法
DK95903485T DK0739413T3 (da) 1993-12-06 1994-12-05 Fremgangsmåde til udvælgelse af specifikke bakteriofager
PCT/SE1994/001166 WO1995016027A1 (en) 1993-12-06 1994-12-05 Method of selecting specific bacteriophages
DE69417446T DE69417446T2 (de) 1993-12-06 1994-12-05 Methode zur selektion spezifischer bakteriophagen
ES95903485T ES2132601T3 (es) 1993-12-06 1994-12-05 Procedimiento para la seleccion de bacteriofagos especificos.
GR990401295T GR3030210T3 (en) 1993-12-06 1999-05-13 Method of selecting specific bacteriophages

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9304060A SE9304060D0 (sv) 1993-12-06 1993-12-06 Sätt att selektera specifika bakteriofager

Publications (1)

Publication Number Publication Date
SE9304060D0 true SE9304060D0 (sv) 1993-12-06

Family

ID=20392016

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9304060A SE9304060D0 (sv) 1993-12-06 1993-12-06 Sätt att selektera specifika bakteriofager

Country Status (12)

Country Link
US (1) US5712089A (de)
EP (1) EP0739413B1 (de)
JP (1) JP3574135B2 (de)
AT (1) ATE178092T1 (de)
AU (1) AU686292B2 (de)
CA (1) CA2178205A1 (de)
DE (1) DE69417446T2 (de)
DK (1) DK0739413T3 (de)
ES (1) ES2132601T3 (de)
GR (1) GR3030210T3 (de)
SE (1) SE9304060D0 (de)
WO (1) WO1995016027A1 (de)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992009690A2 (en) * 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
GB9500851D0 (en) * 1995-01-17 1995-03-08 Bionvent International Ab Method of selecting specific bacteriophages
SE9503151D0 (sv) * 1995-09-13 1995-09-13 Bioinvent Internatioal Ab Combined ligand and receptor display
SE506771C2 (sv) * 1996-02-06 1998-02-09 Gotpat 105 Ab Fusionsprotein, bakteriofag uttryckande proteinet, dessas användning samt hybridoma celler och monoklonaler producerade av cellerna
US6174915B1 (en) 1997-03-25 2001-01-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
US6497874B1 (en) 1997-02-05 2002-12-24 Maardh Sven Recombinant phages
GB9716900D0 (en) * 1997-08-08 1997-10-15 Bioinvent Int Ab Method for selecting phage displaying ligand binders
EP1518927A3 (de) * 1998-02-11 2005-06-22 Maxygen, Inc. Optimisierung von Immunmodulierungsfähigkeiten von genetischen Impfstoffe
WO1999041369A2 (en) * 1998-02-11 1999-08-19 Maxygen, Inc. Genetic vaccine vector engineering
US7153655B2 (en) * 1998-06-16 2006-12-26 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function involving the use of exonuclease enzyme and two populations of parent polynucleotide sequence
WO2000006717A2 (en) 1998-07-27 2000-02-10 Genentech, Inc. Improved transformation efficiency in phage display through modification of a coat protein
IL149809A0 (en) * 1999-12-15 2002-11-10 Genentech Inc Shotgun scanning, a combinatorial method for mapping functional protein epitopes
DK2857516T3 (en) 2000-04-11 2017-08-07 Genentech Inc Multivalent antibodies and uses thereof
US6686154B2 (en) * 2000-06-05 2004-02-03 Zyomyx, Inc. Screening of phage displayed peptides without clearing of the cell culture
JP2004509078A (ja) 2000-07-27 2004-03-25 ジェネンテック・インコーポレーテッド Ａｐｏ−２ＬレセプターアゴニストとＣＰＴ−１１の相乗作用
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US6958213B2 (en) 2000-12-12 2005-10-25 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function
US20020086292A1 (en) 2000-12-22 2002-07-04 Shigeaki Harayama Synthesis of hybrid polynucleotide molecules using single-stranded polynucleotide molecules
DK1504098T4 (da) * 2002-05-17 2011-05-23 Alligator Bioscience Ab Fremgangsmåde til molekyulær udvikling in vitro af proteinfunktion
DE60336406D1 (de) 2002-10-16 2011-04-28 Purdue Pharma Lp Antikörper, die an zellassoziiertes ca 125/0722p binden, und verfahren zu deren anwendung
GB2400851B (en) * 2003-04-25 2004-12-15 Bioinvent Int Ab Identifying binding of a polypeptide to a polypeptide target
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
WO2005118647A2 (en) * 2004-05-18 2005-12-15 Genentech, Inc. M13 virus major coat protein variants for c-terminal and bi-terminal display of a heterologous protein
GB2432366B (en) * 2005-11-19 2007-11-21 Alligator Bioscience Ab A method for in vitro molecular evolution of protein function
SI2271670T1 (sl) 2008-03-14 2015-01-30 Allergan, Inc. Preizkusi aktivnosti serotipa A botulin toksina na podlagi imunosti
MX2010014358A (es) 2008-06-20 2011-07-04 Wyeth Llc Composiciones y metodos de uso del orf1358 de cepas estreptococicas beta-hemoliticas.
JP5623401B2 (ja) 2008-08-14 2014-11-12 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド 抗ｉｌ−１２／ｉｌ−２３抗体
CA3073384A1 (en) * 2008-09-05 2010-03-11 President And Fellows Of Harvard College Continuous directed evolution of proteins and nucleic acids
EP2406629B9 (de) 2009-03-13 2014-03-26 Allergan, Inc. Immunbasierte testverfahren für endopeptidase-aktivität mit neuem ziel
CA2807244A1 (en) * 2010-08-27 2012-03-01 University Of Zurich A novel diagnostic and therapeutic target in inflammatory and/or cardiovascular diseases
US9394537B2 (en) 2010-12-22 2016-07-19 President And Fellows Of Harvard College Continuous directed evolution
GB201200259D0 (en) 2012-01-09 2012-02-22 Ohlin Per M Novel therapies
EP2970917A2 (de) 2013-03-15 2016-01-20 Altria Client Services LLC Bakteriophage und verfahren zur herstellung und verwendung
EP3077417A1 (de) 2013-12-08 2016-10-12 Peptcell Limited Hiv-antigene und antikörper und zusammensetzungen, verfahren und verwendungen davon
DK3087098T3 (da) 2013-12-24 2020-06-08 Janssen Pharmaceutica Nv Anti-Vista-antistoffer og -fragmenter
EP3097196B1 (de) 2014-01-20 2019-09-11 President and Fellows of Harvard College Negativauswahl und stringenzmodulation in systemen der kontinuierlichen evolution
WO2016077052A2 (en) 2014-10-22 2016-05-19 President And Fellows Of Harvard College Evolution of proteases
WO2016123425A1 (en) 2015-01-29 2016-08-04 Altria Client Services Llc Endolysin from bacteriophage against geobacillus and methods of using
US9781929B2 (en) 2015-01-29 2017-10-10 Altria Client Services Llc Bacteriophage and methods of using
US11299729B2 (en) 2015-04-17 2022-04-12 President And Fellows Of Harvard College Vector-based mutagenesis system
CA2990360C (en) 2015-06-24 2024-02-13 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments
US10392674B2 (en) 2015-07-22 2019-08-27 President And Fellows Of Harvard College Evolution of site-specific recombinases
WO2017015559A2 (en) 2015-07-23 2017-01-26 President And Fellows Of Harvard College Evolution of bt toxins
WO2017019895A1 (en) 2015-07-30 2017-02-02 President And Fellows Of Harvard College Evolution of talens
IL294014B2 (en) 2015-10-23 2024-07-01 Harvard College Nucleobase editors and their uses
WO2017137830A1 (en) 2016-02-12 2017-08-17 Janssen Pharmaceutica Nv Anti-vista (b7h5) antibodies
EA201892190A1 (ru) 2016-03-29 2019-04-30 Янссен Байотек, Инк. Лечение псориаза антителом к ил-12 и/или ил-23 с возрастанием интервала между введениями дозы
WO2017175058A1 (en) 2016-04-07 2017-10-12 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
JP2020500152A (ja) 2016-09-30 2020-01-09 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ２３特異的抗体で乾癬を治療する安全かつ有効な方法
EP3312290A1 (de) 2016-10-18 2018-04-25 Ipsen Biopharm Limited Zellulärer vamp-spaltungstest
EP3541422A4 (de) 2016-11-16 2020-05-06 Janssen Biotech, Inc. Verfahren zur behandlung von schuppenflechte mit anti-il-23-spezifischem antikörper
KR20190113858A (ko) 2017-01-30 2019-10-08 얀센 바이오테크 인코포레이티드 활성 건선성 관절염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
MX2019009377A (es) 2017-02-07 2019-12-11 Janssen Biotech Inc Anticuerpos anti-tnf, composiciones y metodos para el tratamiento de la espondilitis anquilosante activa.
US11447809B2 (en) 2017-07-06 2022-09-20 President And Fellows Of Harvard College Evolution of tRNA synthetases
CA3073040A1 (en) 2017-08-25 2019-02-28 President And Fellows Of Harvard College Evolution of bont peptidases
US11624130B2 (en) 2017-09-18 2023-04-11 President And Fellows Of Harvard College Continuous evolution for stabilized proteins
TW201922780A (zh) 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
WO2019150309A1 (en) 2018-02-02 2019-08-08 Hammack Scott Modulators of gpr68 and uses thereof for treating and preventing diseases
IL310216A (en) 2018-03-05 2024-03-01 Janssen Biotech Inc Methods for treating Crohn's disease with a specific anti-IL23 antibody
US11913044B2 (en) 2018-06-14 2024-02-27 President And Fellows Of Harvard College Evolution of cytidine deaminases
WO2020016838A2 (en) 2018-07-18 2020-01-23 Janssen Biotech, Inc. Sustained response predictors after treatment with anti-il23 specific antibody
LT3883606T (lt) 2018-09-24 2023-09-11 Janssen Biotech, Inc. Saugus ir veiksmingas opinio kolito gydymo būdas anti-il12/il23 antikūnu
WO2020104943A2 (en) 2018-11-20 2020-05-28 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-il-23 specific antibody
EP3897722A4 (de) 2018-12-18 2022-09-14 Janssen Biotech, Inc. Sichere und wirksame methode zur behandlung von lupus mit anti-il12/il23-antikörper
BR112021013903A2 (pt) 2019-01-15 2021-09-21 Janssen Biotech, Inc. Composições e métodos de anticorpos anti-tnf para o tratamento da artrite idiopática juvenil
CA3127748A1 (en) 2019-01-23 2020-07-30 Janssen Biotech, Inc. Anti-tnf antibody compositions for use in methods for the treatment of psoriatic arthritis
KR20210142002A (ko) 2019-03-14 2021-11-23 얀센 바이오테크 인코포레이티드 항-tnf 항체 조성물을 생성하기 위한 제조 방법
WO2020183270A1 (en) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Methods for producing anti-tnf antibody compositions
MA55284A (fr) 2019-03-14 2022-01-19 Janssen Biotech Inc Procédés de production de compositions d'anticorps anti-tnf
KR20210141990A (ko) 2019-03-14 2021-11-23 얀센 바이오테크 인코포레이티드 항-il12/il23 항체 조성물을 생성하기 위한 제조 방법
WO2020188466A1 (en) 2019-03-18 2020-09-24 Janssen Biotech, Inc. Method of treating psoriasis in pediatric subjects with anti-il12/il23 antibody
AU2020279987A1 (en) 2019-05-23 2021-11-18 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
CA3142580A1 (en) 2019-06-03 2020-12-10 Janssen Biotech, Inc. Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis
AU2020289070A1 (en) 2019-06-03 2022-02-03 Janssen Biotech, Inc. Anti-TNF antibody compositions, and methods for the treatment of Psoriatic Arthritis
WO2021028752A1 (en) 2019-08-15 2021-02-18 Janssen Biotech, Inc. Anti-tfn antibodies for treating type i diabetes
EP4305061A1 (de) 2021-03-12 2024-01-17 Janssen Biotech, Inc. Sicheres und wirksames verfahren zur behandlung von psoriasisarthritis mit anti-il23-spezifischem antikörper
BR112023018400A2 (pt) 2021-03-12 2023-12-12 Janssen Biotech Inc Método para tratamento de pacientes de artrite psoriática com resposta inadequada à terapia de tnf com anticorpo específico anti-il23
JP2024526315A (ja) 2021-07-09 2024-07-17 ヤンセン バイオテツク，インコーポレーテツド 抗ｔｎｆ抗体組成物を製造するための製造方法
WO2023281462A1 (en) 2021-07-09 2023-01-12 Janssen Biotech, Inc. Manufacturing methods for producing anti-tnf antibody compositions
CN117916260A (zh) 2021-07-09 2024-04-19 詹森生物科技公司 用于制备抗il12/il23抗体组合物的制造方法
IL312401A (en) 2021-10-29 2024-06-01 Janssen Biotech Inc Methods for treating Crohn's disease with a specific anti-IL23 antibody
US20230151087A1 (en) 2021-11-15 2023-05-18 Janssen Biotech, Inc. Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
IL313021A (en) 2021-11-23 2024-07-01 Janssen Biotech Inc A method for treating ulcerative colitis with a specific anti-IL23 antibody
WO2023187707A1 (en) 2022-03-30 2023-10-05 Janssen Biotech, Inc. Method of treating mild to moderate psoriasis with il-23 specific antibody
WO2023223265A1 (en) 2022-05-18 2023-11-23 Janssen Biotech, Inc. Method for evaluating and treating psoriatic arthritis with il23 antibody
US20240199734A1 (en) 2022-11-22 2024-06-20 Janssen Biotech, Inc. Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4122599C2 (de) * 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
EP0614989A1 (de) * 1993-02-17 1994-09-14 MorphoSys AG Verfahren für in vivo Selektion von Ligandenbindende Proteine

Also Published As

Publication number Publication date
GR3030210T3 (en) 1999-08-31
EP0739413A1 (de) 1996-10-30
JP3574135B2 (ja) 2004-10-06
DK0739413T3 (da) 1999-10-11
AU686292B2 (en) 1998-02-05
DE69417446D1 (de) 1999-04-29
CA2178205A1 (en) 1995-06-15
ATE178092T1 (de) 1999-04-15
DE69417446T2 (de) 1999-09-02
AU1252195A (en) 1995-06-27
EP0739413B1 (de) 1999-03-24
WO1995016027A1 (en) 1995-06-15
ES2132601T3 (es) 1999-08-16
JPH09506000A (ja) 1997-06-17
US5712089A (en) 1998-01-27

Similar Documents

Publication Publication Date Title
SE9304060D0 (sv) Sätt att selektera specifika bakteriofager
ATE169058T1 (de) Gegen cd3 gerichtete antikörper
NO964650D0 (no) LAG-3 protein-opplöselige polypeptidfraksjoner, fremgangsmåte for fremstilling, teraupeutisk preparat og anti-idiotype antistoff
WO1999062526A3 (en) Use of genetically engineered antibodies to cd38 to treat multiple myeloma
ES2106195T3 (es) Anticuerpo igg aglicosilado anti cd3.
DK0523395T3 (da) Seroreaktive områder på proteinerne E1 og E2 i HPV 16
ATE301471T1 (de) Verwendung von antikörpen gegen cd45ro leukozytenantigen zur immunmodulation
DE69833106D1 (de) Antigene fusionsproteine, die gal-alpha-1,3-gal-epitope enthalten.
GR3036906T3 (en) Monoclonal antibody which specifically binds to tumor vascular endothelium and uses thereof.
FI854187L (fi) Immunoanalyser foer denaturerade proteinanalyser, saerskilt hb alc, samt antikroppar anvaendbara i dessa.
DK0626861T3 (da) Behandling af astma.
WO1999003987A3 (fr) Epitopes du vrs et anticorps les comportant, utiles dans le diagnostic et la therapie
PT90265A (pt) Metodo rapido para analise de mutacoes
NZ305083A (en) Use of cd40 binding proteins (a cd40 ligand or monoclonal antibody that specifically binds to cd40) for stimulating a immune response
ATE206621T1 (de) Il-8 antagonisten zur behandlung von asthma
DK0547200T3 (da) Rekombinante antistoffer på overfladen af E. coli
CA2126182A1 (en) Humanized antibodies reactive with gpiib/iiia
HUT69623A (en) Use of endotheli- leukocyte adhesion molecule-1 and antibodies thereto in the treatment of asthma
AU1626492A (en) Monoclonal antibodies against the plasmin-antiplasmin complex, a method for the preparation thereof and the use thereof
ATE328088T1 (de) Transketolase-verwandtes protein
KR890009417A (ko) 모노크로날 항체의 제조방법 및 그것의 이용방법
DK0597043T3 (da) Porcine adipocytantigener og deres anvendelse til immunologisk bekæmpelse af fedt
HUP0003029A2 (hu) Ankrod specifikus monoklonális antitestek, antitestfragmentumok, keverékeik és alkalmazásuk
GB2333295A (en) Modified protein G and fragments thereof
IT1267667B1 (it) Metodo per il dosaggio di una variante della proteina alfa-1-antitripsina